Metis Global Partners LLC Acquires 1,405 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Metis Global Partners LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 47.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,380 shares of the biopharmaceutical company’s stock after purchasing an additional 1,405 shares during the quarter. Metis Global Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $1,205,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Souders Financial Advisors raised its position in shares of Alnylam Pharmaceuticals by 1.0% during the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares during the last quarter. Huntington National Bank grew its stake in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Alnylam Pharmaceuticals by 11.1% in the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 57 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 60 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $235.56 on Friday. The stock has a market cap of $30.38 billion, a price-to-earnings ratio of -89.91 and a beta of 0.39. The firm has a 50-day moving average of $274.95 and a two-hundred day moving average of $234.93. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.15 earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. This represents a 16.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. TD Cowen raised their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $294.50.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.